NasdaqCM:VKTXBiotechs
Viking Therapeutics (VKTX) Valuation In Focus As VK2735 Advances In GLP 1 Weight Loss Trials
Viking Therapeutics (VKTX) is back in focus after reporting a full year 2025 net loss of US$359.64 million and a wider basic loss per share, while advancing weight loss candidate VK2735 through late stage trials.
See our latest analysis for Viking Therapeutics.
At a share price of US$31.03, Viking Therapeutics has a 7 day share price return of 7.00%, while the 90 day share price return of 12.49% and year to date share price return of 12.39% suggest momentum has cooled compared with its very...